ATE511841T1 - Verfahren zur verwendung von aminopyrin- zusammensetzungen mit verzögerter freisetzung - Google Patents
Verfahren zur verwendung von aminopyrin- zusammensetzungen mit verzögerter freisetzungInfo
- Publication number
- ATE511841T1 ATE511841T1 AT05732613T AT05732613T ATE511841T1 AT E511841 T1 ATE511841 T1 AT E511841T1 AT 05732613 T AT05732613 T AT 05732613T AT 05732613 T AT05732613 T AT 05732613T AT E511841 T1 ATE511841 T1 AT E511841T1
- Authority
- AT
- Austria
- Prior art keywords
- composition
- sustained release
- aminopyrine
- compositions
- treatment
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 238000013268 sustained release Methods 0.000 title abstract 3
- 239000012730 sustained-release form Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- RMMXTBMQSGEXHJ-UHFFFAOYSA-N Aminophenazone Chemical compound O=C1C(N(C)C)=C(C)N(C)N1C1=CC=CC=C1 RMMXTBMQSGEXHJ-UHFFFAOYSA-N 0.000 title 1
- 229960000212 aminophenazone Drugs 0.000 title 1
- 150000003927 aminopyridines Chemical class 0.000 abstract 2
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 229960004979 fampridine Drugs 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000036470 plasma concentration Effects 0.000 abstract 1
- 230000004043 responsiveness Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56089404P | 2004-04-09 | 2004-04-09 | |
| US11/102,559 US8354437B2 (en) | 2004-04-09 | 2005-04-08 | Method of using sustained release aminopyridine compositions |
| PCT/US2005/012427 WO2005099701A2 (en) | 2004-04-09 | 2005-04-11 | Methods of using sustained release aminopyridine compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE511841T1 true ATE511841T1 (de) | 2011-06-15 |
Family
ID=35061389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05732613T ATE511841T1 (de) | 2004-04-09 | 2005-04-11 | Verfahren zur verwendung von aminopyrin- zusammensetzungen mit verzögerter freisetzung |
Country Status (21)
| Country | Link |
|---|---|
| US (13) | US8354437B2 (enExample) |
| EP (5) | EP3922248A1 (enExample) |
| JP (4) | JP5736100B2 (enExample) |
| AT (1) | ATE511841T1 (enExample) |
| AU (1) | AU2005232732B2 (enExample) |
| CA (2) | CA2870734C (enExample) |
| CY (4) | CY1111754T1 (enExample) |
| DK (2) | DK2377536T4 (enExample) |
| ES (2) | ES2367707T5 (enExample) |
| FI (2) | FI1732548T4 (enExample) |
| FR (1) | FR13C0033I2 (enExample) |
| HR (2) | HRP20110497T4 (enExample) |
| HU (1) | HUE046320T2 (enExample) |
| LU (2) | LU91933I2 (enExample) |
| ME (2) | ME01836B (enExample) |
| MX (3) | MXPA06011648A (enExample) |
| PL (2) | PL2377536T5 (enExample) |
| PT (2) | PT1732548E (enExample) |
| RS (2) | RS53371B2 (enExample) |
| SI (2) | SI2377536T2 (enExample) |
| WO (1) | WO2005099701A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8007826B2 (en) * | 2003-12-11 | 2011-08-30 | Acorda Therapeutics, Inc. | Sustained release aminopyridine composition |
| US8354437B2 (en) | 2004-04-09 | 2013-01-15 | Acorda Therapeutics, Inc. | Method of using sustained release aminopyridine compositions |
| AU2013206188B2 (en) * | 2005-09-23 | 2016-04-14 | Acorda Therapeutics, Inc. | Method, apparatus and software for identifying responders in a clinical environment |
| CN101827522A (zh) * | 2008-09-10 | 2010-09-08 | 阿索尔达治疗股份有限公司 | 持续释放氨基吡啶组合物的使用方法 |
| SG173641A1 (en) * | 2009-02-11 | 2011-09-29 | Acorda Therapeutics Inc | Compositions and methods for extended therapy with aminopyridines |
| JO3348B1 (ar) * | 2009-08-11 | 2019-03-13 | Acorda Therapeutics Inc | استخدام 4- بايريدين امينو لتحسين الادراك العصبي و/او التلف النفسي لدى مرضى يعانون من نقص النُخاعين وغير ذلك من امراض الجهاز العصبي |
| AR078323A1 (es) * | 2009-09-04 | 2011-11-02 | Acorda Therapeutics Inc | Tratamiento con fampridina de liberacion sostenida en pacientes con esclerosis multiple |
| EP2995305B1 (en) | 2011-01-28 | 2020-03-04 | Acorda Therapeutics, Inc. | Use of potassium channel blockers to treat cerebral palsy |
| US8924325B1 (en) * | 2011-02-08 | 2014-12-30 | Lockheed Martin Corporation | Computerized target hostility determination and countermeasure |
| US10793893B2 (en) | 2011-06-30 | 2020-10-06 | Serb Sa | Methods of administering 3,4-diaminopyridine |
| TWI592156B (zh) | 2011-10-04 | 2017-07-21 | 艾可達醫療公司 | 使用胺基吡啶以治療與中風有關之感覺動作損傷之方法 |
| EP3381455A1 (en) | 2012-02-13 | 2018-10-03 | Acorda Therapeutics, Inc. | Methods for treating an impairment in gait and/or balance in patients with multiple sclerosis using an aminopyridine |
| WO2014028387A1 (en) | 2012-08-13 | 2014-02-20 | Acorda Therapeutics, Inc. | Methods for improving walking capacity in patients with multiple sclerosis using an aminopyridine |
| WO2014093475A1 (en) | 2012-12-11 | 2014-06-19 | Acorda Therapeutics, Inc. | Methods for treating parkinson's disease using aminopyridines |
| CA3081513C (en) | 2013-03-14 | 2022-06-21 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
| WO2014151752A1 (en) * | 2013-03-15 | 2014-09-25 | University Of Rochester | Composition and methods for the treatment of peripheral nerve injury |
| EP3243516A1 (en) | 2013-04-15 | 2017-11-15 | Acorda Therapeutics, Inc. | Methods for treating sensorimotor impairments associated with certain types of stroke using aminopyridines |
| SMT202100443T1 (it) | 2015-02-08 | 2021-09-14 | Alkermes Pharma Ireland Ltd | Composizioni di profarmaci di monometilfumarato |
| RU2580837C1 (ru) * | 2015-05-05 | 2016-04-10 | Федеральное Государственное Автономное Образовательное Учреждение Высшего Профессионального Образования "Московский Физико-Технический Институт (Государственный Университет)" | Кристаллогидрат 4-аминопиридина, способ его получения, фармацевтическая композиция и способ лечения и/или профилактики на её основе |
| US10172842B2 (en) | 2015-09-11 | 2019-01-08 | PharmaDax Inc. | Sustained release oral dosage form containing dalfampridine |
| US20180344649A1 (en) | 2015-09-29 | 2018-12-06 | Acorda Therapeutics, Inc. | Sustained release compositions of 4-aminopyridine |
| EP3606510B1 (en) | 2017-04-06 | 2025-12-10 | Merz Pharmaceuticals, LLC | Sustained release compositions of 4-aminopyridine |
| TR2024006607A1 (tr) * | 2024-05-28 | 2025-12-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | The prolonged-release tablet comprising fampridine |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1082804A (en) | 1912-11-19 | 1913-12-30 | Gerald G Griffin | Confetti-machine. |
| US3065143A (en) | 1960-04-19 | 1962-11-20 | Richardson Merrell Inc | Sustained release tablet |
| CH415963A (de) | 1964-09-04 | 1966-06-30 | Wander Ag Dr A | Masse zur Herstellung von Tabletten mit protrahierter Wirkung |
| US3538214A (en) | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
| US4508715A (en) | 1981-07-01 | 1985-04-02 | University Of Georgia Research Foundation, Inc. | Antagonism of central nervous system drugs by the administration of 4-aminopyridine alone or in combination with other drugs |
| US4386095A (en) | 1982-02-22 | 1983-05-31 | Cornell Research Foundation, Inc. | Diaminopyridines to improve cognition |
| IE53703B1 (en) | 1982-12-13 | 1989-01-18 | Elan Corp Plc | Drug delivery device |
| IE54286B1 (en) | 1983-01-18 | 1989-08-16 | Elan Corp Plc | Drug delivery device |
| US4851230A (en) | 1983-04-07 | 1989-07-25 | Bristol-Myers Company | Capsule shaped tablets |
| IE56459B1 (en) | 1983-12-21 | 1991-08-14 | Elan Corp Ltd | Controlled absorption pharmaceutical formulation |
| US4894240A (en) | 1983-12-22 | 1990-01-16 | Elan Corporation Plc | Controlled absorption diltiazem formulation for once-daily administration |
| IE56999B1 (en) | 1983-12-22 | 1992-03-11 | Elan Corp Plc | Pharmaceutical formulation |
| US4562196A (en) | 1984-04-06 | 1985-12-31 | Nelson Research & Development | 2,4-Diaminopyridine as a pharmacologic agent |
| JPS6124516A (ja) | 1984-07-12 | 1986-02-03 | Fujisawa Pharmaceut Co Ltd | 持続性錠剤 |
| US4812447A (en) | 1985-10-22 | 1989-03-14 | City Of Hope | Method for the treatment of nervous system degeneration |
| US4760092A (en) | 1985-10-29 | 1988-07-26 | The Rockefeller University | Treatment of demyelinating diseases |
| US4832957A (en) | 1987-12-11 | 1989-05-23 | Merck & Co., Inc. | Controlled release combination of carbidopa/levodopa |
| IL86170A (en) | 1987-05-01 | 1992-12-01 | Elan Transdermal Ltd | Preparations and compositions comprising nicotine for percutaneous administration |
| IE64726B1 (en) | 1987-11-20 | 1995-08-23 | Elan Corp Plc | Pharmaceutical formulations for preventing drug tolerance |
| FI895821A7 (fi) | 1988-12-07 | 1990-06-08 | The Wellcome Foundation Ltd | Farmaseuttisesti aktivisia CNS-yhdisteitä |
| US4948581A (en) | 1989-02-17 | 1990-08-14 | Dojin Iyaku-Kako Co., Ltd. | Long acting diclofenac sodium preparation |
| IE82916B1 (en) | 1990-11-02 | 2003-06-11 | Elan Corp Plc | Formulations and their use in the treatment of neurological diseases |
| TW200462B (enExample) | 1990-09-27 | 1993-02-21 | Hoechst Roussel Pharma | |
| CA2085785C (en) | 1992-12-18 | 2005-03-15 | Robert R. Hansebout | The use of 4-aminopyridine in the treatment of a neurological condition |
| DE4321030A1 (de) * | 1993-06-24 | 1995-01-05 | Bayer Ag | 4-bicyclisch substituierte Dihydropyridine, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimittel |
| US5451409A (en) | 1993-11-22 | 1995-09-19 | Rencher; William F. | Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends |
| KR100354702B1 (ko) | 1993-11-23 | 2002-12-28 | 유로-셀티크 소시에떼 아노뉨 | 약학조성물의제조방법및서방형조성물 |
| US5952357A (en) | 1993-12-23 | 1999-09-14 | Cornell Research Foundation, Inc. | Treating diseases of the anterior horn cells |
| US6284473B1 (en) | 1995-10-02 | 2001-09-04 | Uab Research Foundation | P-cresol sulfate, a component of urinary myelin basic protein-like material, as a correlate of multiple sclerosis status |
| US7179486B1 (en) | 1997-04-01 | 2007-02-20 | Nostrum Pharmaceuticals, Inc. | Process for preparing sustained release tablets |
| US6288026B1 (en) | 1999-02-24 | 2001-09-11 | Heinrich Exner | Process and composition for treating diseases with an oil-in-water emulsion |
| US6600399B1 (en) | 2002-02-05 | 2003-07-29 | Roland Pierre Trandafir | Transducer motor/generator assembly |
| WO2004082684A1 (en) | 2003-03-17 | 2004-09-30 | Acorda Therapeutics | Stable oral formulations of aminopyridines and uses thereof |
| AU2004226876A1 (en) | 2003-04-03 | 2004-10-14 | Prana Biotechnology Ltd | Treatment of neurological conditions |
| CA2534711A1 (en) | 2003-08-01 | 2005-02-10 | Medarex, Inc. | Combination therapies for multiple sclerosis |
| US8007826B2 (en) | 2003-12-11 | 2011-08-30 | Acorda Therapeutics, Inc. | Sustained release aminopyridine composition |
| US8354437B2 (en) | 2004-04-09 | 2013-01-15 | Acorda Therapeutics, Inc. | Method of using sustained release aminopyridine compositions |
| WO2006130726A2 (en) | 2005-06-01 | 2006-12-07 | Teva Pharmaceutical Industries, Ltd. | Use of ladostigil for the treatment of multiple sclerosis |
| CA2623955C (en) | 2005-09-23 | 2019-12-17 | Acorda Therapeutics, Inc. | Method, apparatus and software for identifying responders in a clinical environment |
| TWM331106U (en) * | 2007-11-12 | 2008-04-21 | Syspotek Corp | Solution counter with temperature sensor |
| CN101827522A (zh) | 2008-09-10 | 2010-09-08 | 阿索尔达治疗股份有限公司 | 持续释放氨基吡啶组合物的使用方法 |
| WO2010090730A1 (en) | 2009-02-03 | 2010-08-12 | Acorda Therapeutics, Inc. | Method, apparatus and software for identifying responders in a clinical environment |
| SG173641A1 (en) | 2009-02-11 | 2011-09-29 | Acorda Therapeutics Inc | Compositions and methods for extended therapy with aminopyridines |
| JO3348B1 (ar) | 2009-08-11 | 2019-03-13 | Acorda Therapeutics Inc | استخدام 4- بايريدين امينو لتحسين الادراك العصبي و/او التلف النفسي لدى مرضى يعانون من نقص النُخاعين وغير ذلك من امراض الجهاز العصبي |
| AR078323A1 (es) | 2009-09-04 | 2011-11-02 | Acorda Therapeutics Inc | Tratamiento con fampridina de liberacion sostenida en pacientes con esclerosis multiple |
| US10255905B2 (en) | 2016-06-10 | 2019-04-09 | Google Llc | Predicting pronunciations with word stress |
-
2005
- 2005-04-08 US US11/102,559 patent/US8354437B2/en not_active Expired - Fee Related
- 2005-04-11 CA CA2870734A patent/CA2870734C/en not_active Expired - Lifetime
- 2005-04-11 EP EP21170762.5A patent/EP3922248A1/en not_active Withdrawn
- 2005-04-11 PT PT05732613T patent/PT1732548E/pt unknown
- 2005-04-11 SI SI200531728T patent/SI2377536T2/sl unknown
- 2005-04-11 ES ES05732613T patent/ES2367707T5/es not_active Expired - Lifetime
- 2005-04-11 ME MEP-2013-48A patent/ME01836B/me unknown
- 2005-04-11 WO PCT/US2005/012427 patent/WO2005099701A2/en not_active Ceased
- 2005-04-11 EP EP11160247.0A patent/EP2377536B2/en not_active Expired - Lifetime
- 2005-04-11 ME MEP-2011-321A patent/ME01721B/me unknown
- 2005-04-11 AT AT05732613T patent/ATE511841T1/de active
- 2005-04-11 PL PL11160247.0T patent/PL2377536T5/pl unknown
- 2005-04-11 MX MXPA06011648A patent/MXPA06011648A/es active IP Right Grant
- 2005-04-11 CA CA2562277A patent/CA2562277C/en not_active Expired - Lifetime
- 2005-04-11 EP EP20110168901 patent/EP2422782A1/en not_active Withdrawn
- 2005-04-11 HR HRP20110497TT patent/HRP20110497T4/hr unknown
- 2005-04-11 RS RS20130183A patent/RS53371B2/sr unknown
- 2005-04-11 SI SI200531307T patent/SI1732548T2/sl unknown
- 2005-04-11 EP EP05732613.4A patent/EP1732548B2/en not_active Expired - Lifetime
- 2005-04-11 AU AU2005232732A patent/AU2005232732B2/en not_active Expired
- 2005-04-11 PT PT111602470T patent/PT2377536E/pt unknown
- 2005-04-11 HU HUE11179067A patent/HUE046320T2/hu unknown
- 2005-04-11 EP EP11179067.1A patent/EP2460521B1/en not_active Revoked
- 2005-04-11 JP JP2007507570A patent/JP5736100B2/ja not_active Expired - Lifetime
- 2005-04-11 PL PL05732613.4T patent/PL1732548T5/pl unknown
- 2005-04-11 DK DK11160247.0T patent/DK2377536T4/da active
- 2005-04-11 DK DK05732613.4T patent/DK1732548T4/da active
- 2005-04-11 RS RS20110321A patent/RS51808B2/sr unknown
- 2005-04-11 ES ES11179067T patent/ES2746354T3/es not_active Expired - Lifetime
- 2005-04-11 MX MX2015004339A patent/MX370434B/es unknown
-
2006
- 2006-10-09 MX MX2019015036A patent/MX2019015036A/es unknown
-
2010
- 2010-06-25 US US12/824,135 patent/US20110166188A1/en not_active Abandoned
- 2010-06-25 US US12/824,133 patent/US20110166187A1/en not_active Abandoned
- 2010-06-25 US US12/824,136 patent/US20110166189A1/en not_active Abandoned
-
2011
- 2011-08-09 CY CY20111100757T patent/CY1111754T1/el unknown
- 2011-11-18 US US13/299,969 patent/US8440703B2/en not_active Expired - Fee Related
-
2012
- 2012-01-18 LU LU91933C patent/LU91933I2/fr unknown
- 2012-01-19 FI FIEP05732613.4T patent/FI1732548T4/fi active
- 2012-01-19 CY CY2012004C patent/CY2012004I2/el unknown
- 2012-03-02 US US13/410,388 patent/US20120164078A1/en not_active Abandoned
- 2012-04-25 JP JP2012100498A patent/JP2012188427A/ja active Pending
-
2013
- 2013-03-14 US US13/829,221 patent/US20140039015A1/en not_active Abandoned
- 2013-04-29 CY CY20131100351T patent/CY1114073T1/el unknown
- 2013-05-14 HR HRP20130424TT patent/HRP20130424T4/hr unknown
- 2013-06-24 FR FR13C0033C patent/FR13C0033I2/fr active Active
- 2013-08-13 FI FIC20130042C patent/FIC20130042I1/fi unknown
- 2013-09-03 LU LU92275C patent/LU92275I2/xx unknown
-
2014
- 2014-11-03 US US14/531,191 patent/US20150080436A1/en not_active Abandoned
- 2014-12-24 JP JP2014259950A patent/JP5914626B2/ja not_active Expired - Fee Related
-
2015
- 2015-06-05 JP JP2015114746A patent/JP2015157861A/ja not_active Withdrawn
-
2016
- 2016-03-23 US US15/079,010 patent/US20160199358A1/en not_active Abandoned
- 2016-11-04 US US15/344,096 patent/US20170071924A1/en not_active Abandoned
-
2017
- 2017-04-07 US US15/482,432 patent/US20170273960A1/en not_active Abandoned
- 2017-04-07 US US15/482,426 patent/US9925173B2/en not_active Expired - Lifetime
-
2018
- 2018-03-12 US US15/918,931 patent/US20180200241A1/en not_active Abandoned
-
2024
- 2024-07-30 CY CY2013035C patent/CY2024026I2/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FIC20130042I1 (fi) | Fampridiini tai sen suola tai solvaatti | |
| UY32109A (es) | Métodos para utilizar composiciones de liberación sostenida de aminopiridina | |
| ATE498395T1 (de) | Allgemein lineare brauseform von fentanyl zur oralen anwendung und verfahren zur verabreichung | |
| DE69433818D1 (de) | Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung | |
| NO20063373L (no) | CD40-antistoff-formuleringer og fremgangsmater | |
| SG151329A1 (en) | Amido compounds and their use as pharmaceuticals | |
| CY1108932T1 (el) | Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων | |
| ATE453646T1 (de) | 3-substituierte n-(aryl- oder heteroaryl)pyrazoä1,5-aüpyrimidine als kinaseinhibitoren | |
| IS6558A (is) | Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni | |
| Heibel et al. | Successful treatment of type I pityriasis rubra pilaris with ixekizumab | |
| EP1781277A4 (en) | COMBINATION PREPARATION | |
| WO2005120542A3 (en) | Methods of treating disease with random copolymers | |
| DE602004029993D1 (de) | Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeit | |
| IL175358A0 (en) | 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease | |
| Deutsch et al. | Unexpected sequel to silver fluoride followed by stannous fluoride treatment of root stumps supporting an overlay denture in an aged‐care patient | |
| ATE402147T1 (de) | 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen | |
| Dennis et al. | Tuberous Sclerosis Psychosis | |
| Simpson | Challenging assumptions: the application of a world views model to involuntary job loss: this thesis is presented in partial fulfillment of the requirements for the Master of Arts in Psychology, at Massey University |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1732548 Country of ref document: EP |